You can help find better treatments for COVID-19 through a high-tech app
UTHealth using app to track long-term COVID-19 effects for new study
The University of Texas Health Science Center is one of eight sites in the country joining the new study to see how the coronavirus is affecting Houstonians.
HOUSTON - Researchers at UTHealth are asking for your help to find better treatments for COVID-19.
They re teaming up with the Centers for Disease Control and using a high-tech app to track long-term effects of the virus.
One thing we ve all learned about COVID-19 is it affects everyone differently. The CDC is gathering every piece of information it can to try to get a better understanding of it.
CHICAGO A recently released study shows that a multimodal pain regimen (MMPR) designed to minimize opioid exposure and relieve acute pain associated with traumatic injury kept patient self-reported pain scores low while also reducing the daily and total amount of opioid drugs given to trauma patients.
Results from the first study of its kind to evaluate an MMPR in a rigorous, randomized controlled trial were published online as an “article in press” by the
Journal of the American College of Surgeons in advance of print.
“Opioids should not be considered the pillar of treatment for acute pain after injury,” said lead study author John A. Harvin, MD, FACS, associate professor for the department of surgery, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth) and trauma surgeon at the Red Duke Trauma Institute at Memorial Hermann-Texas Medical Center.
Multimodal pain regimen minimizes opioid exposure, relieves acute pain in trauma patients
A multimodal pain regimen (MMPR) designed to minimize opioid exposure and relieve acute pain associated with traumatic injury kept patient self-reported pain scores low while also reducing the daily and total amount of opioid drugs given to trauma patients. Results from the first study of its kind to evaluate an MMPR in a rigorous, randomized controlled trial are published online as an article in press by the
Journal of the American College of Surgeons in advance of print. Opioids should not be considered the pillar of treatment for acute pain after injury, said lead study author John A. Harvin, MD, FACS, an associate professor for the department of surgery, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth) and trauma surgeon at the Red Duke Trauma Institute at Memorial Hermann-Texas Medical Center.
Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth).
Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of HIF, which can lead to improved oxygen delivery to tissues. Stabilization of HIF can help to dampen alveolar inflammation, a key problem that patients with COVID-19-associated lung disease are facing when they develop ARDS. The drug is investigational in the U.S. but has been
First patient enrolled in Phase II clinical trial of stem cell therapy for traumatic injuries
The first patient has enrolled in a Phase II clinical trial evaluating a stem cell therapy for the potential early treatment of traumatic injuries and their subsequent complications at The University of Texas Health Science Center at Houston (UTHealth).
The MATRICS-1 (MultiStem
® Administration for Trauma Related Inflammation and Complications) study is being conducted at Memorial Hermann-Texas Medical Center.
According to the Centers for Disease Control (CDC), trauma is the leading cause of death for individuals under the age of 45 and the third leading cause of death in the U.S., accounting for approximately 180,000 fatalities each year. It is also a leading cause of serious disability, especially among young people and members of the military that suffer trauma.